Alkermes begins rolling NDA submission for ALKS 5461 in MDD

Alkermes plc (NASDAQ:ALKS) began submission of a rolling NDA to FDA for ALKS 5461 as adjunctive treatment of major depressive disorder (MDD). The company plans to complete the submission by year end...